BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03502577

Recruitment Status : Terminated (Closed per SRC Low Accrual Policy)

First Posted : April 18, 2018

Last Update Posted : January 8, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

The Leukemia and Lymphoma Society

Information provided by (Responsible Party):

Fred Hutchinson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	April 20, 2022
Actual Study Completion Date :	April 20, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M, Comstock ML, Rajan A, Patel BKR, Voutsinas JM, Wu Q, Liu L, Cowan AJ, Wood BL, Green DJ, Riddell SR. gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.

To Top